Why Juno Therapeutics Shares Vaulted 46% Higher in August
After Gilead Sciences (NASDAQ: GILD) scooped up competitor Kite Pharma (NASDAQ: KITE) for $11.9 billion and Novartis (NYSE: NVS) secured an approval from the Food and Drug Administration for Kymriah, shares of Juno Therapeutics (NASDAQ: JUNO) skyrocketed 46% in August, according to S&P Global Market Intelligence.
Juno Therapeutics hasn't been in the lead in the race to develop cellular therapies for cancer treatment for a while, but that didn't stop investors from flocking to its shares following key advances at its top CAR-T competitors.
IMAGE SOURCE: GETTY IMAGES.
Source: Fool.com
Gilead Sciences Inc Stock
€61.58
-1.250%
With 12 Buy predictions and only 1 Sell predictions the community sentiment for the stock is positive.
As a result the target price of 86 € shows a positive potential of 39.66% compared to the current price of 61.58 € for Gilead Sciences Inc.
